Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback